Stock 4RY AKESO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Akeso, Inc. BOERSE MUENCHEN

Equities

4RY

KYG0146B1032

Biotechnology & Medical Research

Market Closed - BOERSE MUENCHEN
Other stock markets
 20:44:14 28/06/2024 BST 		5-day change 1st Jan Change
4.52 EUR -3.00% Intraday chart for Akeso, Inc. +7.11% -14.72%
06-04 Akeso Expands Territory of License Agreement for Lung Cancer Drug MT
06-03 Summit Therapeutics Inc. Expands License Territories for Ivonescimab CI

Valuation

Fiscal Period: Dicembre 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 25,172 22,635 31,941 35,470 30,420 - -
Enterprise Value (EV) 1 22,680 20,843 31,716 36,896 32,130 30,824 30,126
P/E ratio -19.4 x -21 x -26.7 x 17.4 x -67.2 x 132 x 24.7 x
Yield - - - - - - -
Capitalization / Revenue - 100 x 38.1 x 7.84 x 11.6 x 7.35 x 5.03 x
EV / Revenue - 92.4 x 37.9 x 8.15 x 12.3 x 7.45 x 4.98 x
EV / EBITDA -17.6 x -16 x -25.9 x 16.8 x -113 x 60.2 x 20.3 x
EV / FCF -19.3 x -12.1 x -15.5 x 23.2 x -47.2 x -582 x 25.8 x
FCF Yield -5.17% -8.24% -6.44% 4.3% -2.12% -0.17% 3.88%
Price to Book 6.31 x 7.16 x 11.9 x 7.53 x 6.53 x 5.84 x 4.65 x
Nbr of stocks (in thousands) 787,057 817,057 841,057 841,057 865,857 - -
Reference price 2 31.98 27.70 37.98 42.17 35.13 35.13 35.13
Announcement Date 31/03/21 30/03/22 15/03/23 18/03/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Dicembre 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - 225.6 837.7 4,526 2,620 4,138 6,044
EBITDA 1 -1,290 -1,302 -1,225 2,191 -285.5 512.1 1,482
EBIT 1 -1,313 -1,351 -1,331 2,049 -458 279.3 1,313
Operating Margin - -598.89% -158.92% 45.26% -17.48% 6.75% 21.72%
Earnings before Tax (EBT) 1 -1,321 -1,258 -1,422 1,943 -484.5 240.8 1,443
Net income 1 -1,177 -1,075 -1,168 2,028 -432.4 221.6 1,210
Net margin - -476.42% -139.48% 44.81% -16.5% 5.36% 20.03%
EPS 2 -1.650 -1.320 -1.420 2.420 -0.5232 0.2655 1.424
Free Cash Flow 1 -1,173 -1,717 -2,043 1,588 -681 -52.99 1,167
FCF margin - -761.15% -243.88% 35.09% -25.99% -1.28% 19.32%
FCF Conversion (EBITDA) - - - 72.48% - - 78.75%
FCF Conversion (Net income) - - - 78.31% - - 96.45%
Dividend per Share 2 - - - - - - -
Announcement Date 31/03/21 30/03/22 15/03/23 18/03/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 S1 2021 S2 2022 S1 2022 S2 2023 S1 2023 S2
Net sales 1 - 97.03 - 674.5 3,677 849.4
EBITDA - - - - - -
EBIT 1 - - - - 2,482 -433.9
Operating Margin - - - - 67.51% -51.09%
Earnings before Tax (EBT) 1 - -812 - -730.3 2,490 -547
Net income 1 -424.9 - -630.4 -538 2,525 -496.7
Net margin - - - -79.75% 68.67% -58.48%
EPS -0.5200 - -0.7700 - - -
Dividend per Share - - - - - -
Announcement Date 23/09/21 30/03/22 23/08/22 15/03/23 29/08/23 18/03/24
1CNY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - 1,425 1,711 404 -
Net Cash position 1 2,492 1,792 225 - - - 294
Leverage (Debt/EBITDA) - - - 0.6505 x -5.991 x 0.7894 x -
Free Cash Flow 1 -1,173 -1,717 -2,043 1,588 -681 -53 1,167
ROE (net income / shareholders' equity) -74% -33.9% -40.3% 55.4% -8.69% 5.1% 19.8%
ROA (Net income/ Total Assets) -42.6% -24.8% -22.7% 27.6% -3.96% 3.6% 11.8%
Assets 1 2,765 4,331 5,151 7,339 10,921 6,157 10,271
Book Value Per Share 2 5.060 3.870 3.200 5.600 5.380 6.020 7.550
Cash Flow per Share 2 -0.9800 -1.230 -1.500 2.950 -0.2900 0.4300 1.640
Capex 1 556 716 802 879 356 308 285
Capex / Sales - 317.39% 95.8% 19.43% 13.59% 7.43% 4.72%
Announcement Date 31/03/21 30/03/22 15/03/23 18/03/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Akeso, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
35.13 CNY
Average target price
55.12 CNY
Spread / Average Target
+56.90%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+15.20% 121B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+19.67% 113B
ARGENX SE Stock argenx SE
+18.95% 26.02B
BIONTECH SE Stock BioNTech SE
-23.86% 19.39B
GENMAB A/S Stock Genmab A/S
-19.03% 15.91B
BEIGENE, LTD. Stock BeiGene, Ltd.
-20.90% 15.09B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-46.14% 15.06B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+63.85% 14.93B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.49% 13.85B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 9926 Stock
  4. 4RY Stock
  5. Financials Akeso, Inc.